BioCentriq Raises $29.2M in Series A Funding

BioCentriq, a Newark, NJ-based cell-based therapy contract development and manufacturing organization (CDMO), raised $29.2M in Series A funding.

The backers were not disclosed.

The company intends to use the funds to enhance its facilities, invest in advanced technologies, and expand its team.

Led by CEO James Park, BioCentriq specializes in cell therapy contract development and manufacturing, with a track record transferring, developing, and manufacturing GMP drug product for use in clinical trials. The company’s comprehensive suite of services includes process development, manufacturing, and analytical testing ensuring seamless and efficient development of cell-based therapies for diverse therapeutic areas.

That’s awesome news! Sending a heartfelt congratulations to BioCentriq and their team on the fantastic achievement of raising $29.2M in Series A funding. Here’s to the next chapter of success and innovation! 🎉🌟

~ Dr Shishir said Gupta founder & CEO of StartupLanes 

About us: StartupLanes is an ecosystem for Startups and Investors. Collaborate or find a co-founder, it’s a platform for Entrepreneurs. We love startups! A place for Angel Investors and Venture Capitalists to find investing opportunities in startups. Validate your idea, Learn & Execute.

Startups looking for funding may apply through StartupLanes Funding Application.

Angel Investors Register Free to explore exciting startup investment opportunities.

Scroll to Top